AVITA Medical Inc.’s recent filing unveils that its CFO O’Toole David D acquired Company’s shares for reported $34110.0 on Aug 16. In the deal valued at $17.05 per share,2,000 shares were bought. As a result of this transaction, O’Toole David D now holds 9,000 shares worth roughly $ 0.15 million.
Then, O’Toole David D bought 5,000 shares, generating $89,640 in total proceeds. Upon buying the shares at $17.93, the CFO now owns 7,000 shares.
Before that, O’Toole David D bought 1,000 shares. AVITA Medical Inc. shares valued at $16,150 were divested by the CFO at a price of $16.15 per share. As a result of the transaction, O’Toole David D now holds 2,000 shares, worth roughly $32600.0.
Cantor Fitzgerald initiated its AVITA Medical Inc. [RCEL] rating to an Overweight in a research note published on Friday, June 27, 2023; the price target was $23. PT values the company’s stock at a premium of 29.13 to its Friday closing price.
Price Performance Review of RCEL
On Friday, AVITA Medical Inc. [NASDAQ:RCEL] saw its stock remained unchanged to $16.30. On the same session, the stock had its day’s lowest price of $16.03, but rose to a high of $16.60. Over the last five days, the stock has gained 2.26%. AVITA Medical Inc. shares have risen nearly 146.97% since the year began. Nevertheless, the stocks have risen 163.75% over the past one year. While a 52-week high of $21.70 was reached on 07/17/23, a 52-week low of $4.41 was recorded on 01/03/23. SMA at 50 days reached $17.59, while 200 days put it at $12.85. A total of 85043.0 shares were traded, compared to the trading of 0.14 million shares in the previous session.
Levels Of Support And Resistance For RCEL Stock
The 24-hour chart illustrates a support level at 16.02, which if violated will result in even more drops to 15.74. On the upside, there is a resistance level at 16.59. A further resistance level may holdings at 16.88. The Relative Strength Index (RSI) on the 14-day chart is 42.45, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -0.04, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bearish at 71.81%. Stochastics %K at 22.60% indicates the stock is a holding.
How much short interest is there in AVITA Medical Inc.?
A steep rise in short interest was recorded in AVITA Medical Inc. stocks on Aug 14, 2023, dropping by -0.35 million shares to a total of 0.92 million shares. Yahoo Finance data shows the prior-month short interest on Jul 13, 2023 was 1.27 million shares. There was a decline of -37.85%, which implies that there is a negative sentiment for the stock. In spite of short shares comprising just 3.62% of the overall stock float, the days-to-cover ratio (short ratio) fell to 4.76.
AVITA Medical Inc. [RCEL] – Who Are The Largest Shareholders?
In filings from BlackRock Fund Advisors, it is revealed that the company now owns 1,548,461 shares, or roughly 6.11% of the outstanding RCEL shares. In other words, the investor’s shares have risen by 1,077,008 from its previous 13-F filing of 471453.0. Additionally, The Vanguard Group, Inc. increased 8.64% of its stake after which the total value it holdings stand at $26,313,680, while Geode Capital Management LLC added 90.02% of its stake to hold $9.62 million in the firm. Over the last quarter, SSgA Funds Management, Inc. purchased 364,384 shares of AVITA Medical Inc., while Pura Vida Investments LLC bought -372,601 shares. At present, Millennium Management LLC is holding 274,097 shares valued at $5.55 million. Northern Trust Investments, Inc. owned 217,904 shares of the company at the time of its most recent 13F filing, worth $4.41 million.
According to FactSet, AVITA Medical Inc.’s share price will average $25.97 in the next year, based on opinions of analysts polled by the firm. This is up nearly 53.37 percent from its previous closing price of $16.30. Analysts expect AVITA Medical Inc. stock to reach the higher price of $40.00, while the lowest price estimate is $20.66. However, 9 analysts have rated RCEL stock as a Buy in their predictions for 2023.